{
  "docId": "019de077-5087-71ae-b0e8-0abfd1317859",
  "docSlug": "b6fff97596ca7cba1b2ee8405a1dc7cd",
  "documentTitle": "AstraZeneca | Results Presentation Deck | 38 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 26,
  "pageCount": 38,
  "prevPage": 25,
  "nextPage": 27,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 3,
  "notes": "The slide uses a navigation bar at the top to indicate the current section is 'CEO Opening Remarks'.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-5087-71ae-b0e8-0abfd1317859/26",
  "deckHref": "/decks/019de077-5087-71ae-b0e8-0abfd1317859",
  "deckJsonHref": "/decks/019de077-5087-71ae-b0e8-0abfd1317859.json",
  "deckAnchorHref": "/decks/019de077-5087-71ae-b0e8-0abfd1317859#slide-26",
  "components": [
    {
      "bbox": {
        "h": 0.3,
        "w": 1,
        "x": 0,
        "y": 0.2
      },
      "kind": "image",
      "text": "Background image of a corporate building",
      "attrs": null,
      "subkind": "photo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a00ed4f0-22ef-4e05-bf55-2989197634ff",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.25,
        "x": 0.38,
        "y": 0.6
      },
      "kind": "metric",
      "text": "On track to deliver mid-30s% Core operating margin by 2026",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "46ff4663-0651-43eb-b79d-87bf1eb91ff5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.25,
        "x": 0.7,
        "y": 0.6
      },
      "kind": "metric",
      "text": "Ambition to deliver at least 20 NMEs by 2030",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9a61cbd9-c218-4ded-9daf-59f567486ae5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.25,
        "x": 0.05,
        "y": 0.6
      },
      "kind": "metric",
      "text": "Ambition to deliver $80bn in Total Revenue by 2030",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9d2f8dd2-a0a6-4a38-9e1b-489d209984e3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.25,
        "x": 0.7,
        "y": 0.72
      },
      "kind": "paragraph",
      "text": "Delivered 6 NMEs to date",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a57094a9-6bb6-418a-b5b0-7944addef619",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.3,
        "x": 0.35,
        "y": 0.72
      },
      "kind": "paragraph",
      "text": "Beyond 2026, Core operating margin will be influenced by portfolio evolution and the Company will target at least mid-30s%",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c150cfb7-078e-4d7e-9ab5-66c7111cb7fc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.7,
        "x": 0.02,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "1. 2030 Total Revenue ambition at CER, risk adjusted and not dependent upon future M&A. 2. NMEs approved since November 2023 (Imjudo, Truqap, Voydeya, Wainua, Beyfortus, Airsupra). Appendix: Glossary.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5c73d102-51d0-4111-a8ab-69d96ddb9f20",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.03,
        "y": 0.08
      },
      "kind": "title",
      "text": "On track to deliver on strategic ambitions",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bb71e9c5-823b-4bd0-839a-576f29b9c3d5",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 26,
      "from": 25,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "759013e5-ff1b-4c5c-bc9a-b1a6ff2cd73b",
      "evidence": "The presentation implies that failure to achieve its revenue targets would be a missed opportunity, but does not explicitly discuss the cost of inaction.",
      "position": 0,
      "objective": "What would happen if AstraZeneca failed to achieve its revenue targets?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}